Vaxxinity Q4 EPS $(0.09) Beats $(0.10) Estimate
Portfolio Pulse from Happy Mohamed
Vaxxinity (NASDAQ:VAXX) reported a Q4 EPS loss of $(0.09), surpassing the analyst consensus estimate of $(0.10) by 10%. This represents a 43.75% improvement over the $(0.16) per share loss from the same quarter last year.
March 27, 2024 | 8:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaxxinity reported a smaller than expected Q4 EPS loss of $(0.09), outperforming the consensus estimate of $(0.10) and improving significantly from last year's $(0.16) loss.
Vaxxinity's better-than-expected Q4 earnings report, showing a significant improvement over the previous year, is likely to be viewed positively by investors. This could lead to increased investor confidence and potentially a short-term uptick in VAXX's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100